Trinity Biotech plc: 5%+ holders

Trinity Biotech plc has 8 Schedule 13D or 13G filings on record since 2025-10-24. 3 holders' latest filing reports 5% or more of class a ordinary shares, $0.0001 par value per share. Each figure below is the holder's own, as filed, with the filing linked.

Holders

Purpose of Transaction (Item 4)

Perceptive Advisors LLC

Item 4 of the Schedule 13D is hereby amended to add the following: On April 30, 2026, Credit Fund III, the Issuer and the other Issuer Credit Agreement Parties entered into that certain Limited Waiver and Third Amendment to the Sixth Amended and Restated Credit Agreement (the "Third Amendment"), which, among other things, provided for (i) a limited waiver by Credit Fund III of the Borrower's non-compliance with certain financial covenants contained in the Credit Agreement and (ii) an additional $2.5 million term loan borrowing. In connection with the Third Amendment, the Convertible Note was amended and restated (the "Amended and Restated Note") to increase the aggregate amount of indebtedness thereunder that is convertible into ADSs of the Issuer from US$60,000,000 to US$72,500,000 (as so amended, the "Conversion Cap"), and to reduce the minimum price at which indebtedness under the Convertible Note is convertible into ADSs from $1.03 per ADS to $0.5061 per ADS (as so amended, the "Floor Price"). On April 30, 2026, Credit Fund II, the Issuer and TRIB B entered into Amendment No. 1 to Conversion Rights Agreement (the "CRA Amendment"), pursuant to which the Conversion Rights Agreement was amended to reflect the above-described increase of the Conversion Cap and reduction of the Floor Price. The foregoing descriptions of the Third Amendment, the Amended and Restated Note and the CRA Amendment are not complete and, in each case, are qualified in their entirety by reference …The first part of Item 4 of the SCHEDULE 13D/A filed 2026-05-04; the filing has the rest

DAYLI Partners, Inc.

Item 4 of the Original Schedule 13D is hereby amended by inserting the following new paragraph to the end: On December 2, 2025, DAYLI Holdings and AI n M completed the 2025 MiCo IVD Purchase, following which time the DAYLI Filers have no equity interest in MiCo IVD and do not, directly or indirectly, have any equity interest in the Issuer.Item 4 of the SCHEDULE 13D/A filed 2025-12-15

Timeline

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

All recent stakesThat week's stakes